Concept
Senomorphic vs Senolytic
Last updated 2026-07-02· Last reviewed 2026-07-02· 1 min read
Reviewed by the Ultimate Longevity Bible editorial team. Educational reference — not medical advice. See disclaimer.
Senolytics
Selectively induce apoptosis in senescent cells that have upregulated anti-apoptotic pathways (BCL-2 family, PI3K/AKT). Classic examples:
- Dasatinib + quercetin (D+Q): broad-spectrum; used in early human trials of IPF and diabetic kidney disease.
- Fisetin: plant flavonoid with cleaner safety profile; NIH-funded RCTs.
- Navitoclax and derivatives (UBX0101, UBX1325): targeted BCL-2 inhibitors; Unity Biotechnology's programme.
Senomorphics
Reduce the harmful output of senescent cells without eliminating them:
- Rapamycin and other mTOR inhibitors dampen the SASP.
- Metformin and AMPK activators partially reduce SASP.
- JAK inhibitors (baricitinib, ruxolitinib) block IL-6/STAT3 SASP amplification.
- Resveratrol and polyphenol activators.
When to use which
- Senolytics: acute or cyclic clearance — useful when senescent-cell burden itself is causing tissue dysfunction (fibrosis, osteoarthritis).
- Senomorphics: chronic damping — useful when the SASP inflammation is the primary problem.
- Senomorphic — Concept.
- Judith Campisi — Researcher.
- Rapamycin vs Senolytics — Comparison.
- CDKN1A (p21) — Gene.
- TP53 (p53) — Gene.
Related entries
Cellular senescence, Senolytics, Senotherapeutic, Rapamycin.